SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s arm receives FDA approval for Generic GIumetza extended-release Tablets

22 Jul 2013 Evaluate

Pharma major Lupin‘s U.S. subsidiary- Lupin Pharmaceuticals, Inc. has received final approval for its Metformin Hydrochloride extended release tablets (HCL ER) 500 mg and 1000 mg from the United States Food and Drugs Administration (FDA). According to IMS health data, the total sales of Glumetza HCL ER tablets, 500 mg and 1000 mg in US, for the twelve months ending March, 2013, was approximately $144 million.

Lupin's Metformin HCL ER Tablets, 500 mg and 1000 mg strengths are the AB-rated' generic equivalent of  Santarus, inc’s  Glumetz HCL ER Tablets, 500 mg and 1000 me strengths. Lupin had earlier received the tentative approval for generic GLUMETZA (Metformin Hydrochloride Extended Release Tablets) 1000 mg and 500 mg from the United States Food and Drugs Administration (FDA) in January, 2012.

Metformin HCL ER tablets are biguanide and indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Lupin believes that it is the first applicant to file an ANDA for Glumetza HCL ER Tablets, 500 mg & 1000 mg strengths and as such will be entitled to 180 days of marketing exclusivity.

Lupin Share Price

2342.15 -25.65 (-1.08%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: